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ABSTRACT 
Objective: A novel combination of Tadalafil (TAD) and Dapoxetine HCl (DAP) has been recently introduced into the market for the treatment of 
premature ejaculation. The aim of this work is the development and validation of simple, sensitive and accurate analytical methods for the 
determination of TAD and DAP in their binary mixture without prior separation. 
Methods: Synchronous fluorescence spectroscopic (SFS) methods coupled with continuous wavelet transforms (CWT) and Savitzky-Golay 
(SAVGOL) derivatization technique have been developed.  
Results: Under optimum conditions, TAD and DAP were determined in the concentration ranges of 0.01–3 µg/ml and 0.01–1.2 µg/ml, respectively.  
Conclusion: The developed methods have the requisite accuracy, selectivity, sensitivity and precision and were satisfactorily applied for the 
simultaneous determination of TAD and DAP in bulk powder and pharmaceutical preparations. The results obtained for the analysis of both drugs 
in their pure forms by the proposed methods were statistically compared to those obtained by applying a reported high performance liquid 
chromatographic method (HPLC) method. The statistical comparison showed that there is no significant difference between the proposed methods 
and the reported one with respect to accuracy and precision. 
Keywords: Synchronous fluorescence spectroscopy, Tadalafil, Dapoxetine HCl, Continuous wavelet transforms, Savitzky-Golay technique 
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INTRODUCTION 
Fluorescence Spectroscopy provides a major role in analysis owing 
to its high sensitivity and selectivity compared to UV-spectroscopy. 
Conventional fluorescence methods have limited practical 
applicability as most spectra of complex mixtures often cannot be 
resolved satisfactorily without previous separation. However, this 
can be overcome by using special techniques such as SFS [1]. 
In SFS, both the excitation and emission monochromators are scanned 
simultaneously. The main characteristics of SFS are narrowing of the 
spectral band [2], simplification of emission spectra by the choice of 
suitable Δ λ [3] and contraction of spectral range [4]. This  result in 
sharp and narrow peaks compared to those of conventional spectrum.  
The combination of synchronous and derivative fluorimetry 
enhances minor spectral features and allows more reliable 
identification of chemical species. 
Wavelet transform (WT) was proposed for the approximate 
derivative calculation. It has a major advantage of enhancing the 
signal to noise ratio for calculations of the higher order derivatives 
in contrary to the derivative technique which has a major drawback 
in increasing the noise level in calculations of the higher order 
derivative [5]. WT contains two distinct parts, discrete and continuous 
which were developed independently in several fields [6-8].  
WT methods have been successfully used for the resolution of 
overlapped spectra for the quantitative determination of multi-
component mixtures by means of spectrophotometric methods [9-11]. 
An SAVGOL filter is a digital filter that can be applied to a set of digital 
data points for the purpose of smoothing the data, that is, to increase 
the signal-to-noise ratio without distorting the signal. The method is 
based on established mathematical procedures. It was first developed 
by Savitzky and Golay [12] who published tables of convolution 
coefficients for various polynomials and subset sizes [13]. Some errors 
in the tables have been corrected [14, 15]. The method has been 
extended for the treatment of 2-and 3-dimensional data. 
Tadalafil [fig. 1], is (6R, 12aS)-6-(1,3-benzodioxol-5-yl)-2,3,6, 7,12,12a-
hexahydro-2-methylpyrazino[1’,2’:1,6] pyrido [3,4-b] indole-1,4-dione 
[16]. It is a selective, long-acting PDER5 Rinhibitor [17, 18]. Tadalafil 
has shown to be safe and effective in the treatment of erectile 
dysfunction across a variety of clinical populations [19-22]. 
 
Fig. 1: Chemical structure of Tadalafil 
Dapoxetine HCl (fig. 2), is a short-acting selective serotonin reuptake 
inhibitor (SSRI) developed for the treatment of premature 
ejaculation [23, 24]. Dapoxetine has a unique pharmacokinetic 
profile compared to other SSRIs as it is rapidly absorbed and 
eliminated after oral administration [25-28]. Dapoxetine doesn’t 
have pharmacokinetic interactions with PDE5 inhibitors which 
allow its combination with several PDE5 inhibitors for the treatment 
of premature ejaculation [29]. 
A survey of the literature showed that very few methods have been 
reported for the simultaneous determination of TAD and DAP in 
bulk powder and combined dosage form. The reported methods 
include HPLC coupled with UV detection [30, 31] and a single 
spectrophotometric method [32]. Both drugs were reported to be 
fluorescent [33-35], thus they could be determined by fluorescence 
detection. 
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Fig. 2: Chemical structure of Dapoxetine HCl 
 
The aim of this work is to develop two simple, sensitive and 
selective spectrofluorimetric methods based on the coupling of SFS 
with CWT and SAVGOL derivatization technique for the 
simultaneous determination of TAD and DAP in bulk powder and 
pharmaceutical formulation without prior separation. 
MATERIALS AND METHODS 
Chemicals and reagents 
TAD and DAP standard materials were kindly supplied by El Andalus 
Medical company, 6th
Super Tadarise
 of October City, Giza-Egypt. They were found 
to contain 99.7±0.924 % and 101.07±0.539 %, respectively 
according to a reported HPLC method [30]. 
®
HPLC grade Methanol was Sigma–Aldrich, Germany.  
 tablets (Batch No. ST 1514) labeled to contain 20 
mg TAD and 60 mg DAP per tablet were manufactured by Sunrise 
Remedies Pvt. Ltd., India. 
Instruments and software 
Fluorescence spectra were recorded using a Shimadzu (model: RF 
5301 PC, Japan) spectrofluorometer, equipped with a 150-watt 
Xenon lamp. Slit widths for both the excitation and emission 
monochromators were set at 5 nm. A 1 cm quartz cell was used. The 
computations were done using the Matlab®
Spectral characteristics 
 7.0.1 software. 
The emission spectra of 0.1 µg/ml of each of TAD and DAP in 
methanol were scanned over the range of 240–500 nm as shown in 
[fig. 3]. 
Solutions and calibrations 
Different aliquots of TAD and DAP standard solutions (each, 100 
µg/ml) were transferred into two sets of 10-mL volumetric flasks 
and diluted to volume with methanol to give final concentrations 
equivalent to 0.01–3 µg/ml and 0.01–1.2 µg/ml, respectively. The 
prepared solutions were scanned for their synchronous fluorescence 
spectra using Δ λ of 20 nm. The spectra were transferred to Matlab®
Continuous wavelet transforms (CWT) 
 
7.0.1 for signal processing and analysis.  
The synchronous spectra of TAD and DAP were divided by 0.1 µg/ml 
of DAP and TAD, respectively. The first coefficients of CWT of the 
ratio spectra were then calculated.  
The amplitude values were then plotted versus the corresponding 
concentrations at wavelengths of 302 nm and 342 nm for TAD and 
DAP, respectively. The regression equations were computed. 
Savitzky-Golay (SAVGOL) method 
The first derivative of the synchronous spectra was calculated by 
SAVGOL technique, and the amplitude values were then plotted 
versus the corresponding concentrations at wavelengths of 330 nm 
and 312 nm for TAD and DAP, respectively. The regression 
equations were then computed. 
Analysis of laboratory prepared mixtures 
Five laboratory prepared mixtures of TAD and DAP were prepared 
by transferring suitable aliquots of TAD and DAP from their stock 
solutions (each, 100 µg/ml) into 10-mL volumetric flasks and were 
completed to volume with methanol. The synchronous fluorescence 
spectra of the prepared mixtures were scanned from 240–500 nm 
using Δ λ = 20 and transferred to Matlab® 
Continuous wavelet transforms (CWT) 
for signal processing and 
analysis. 
The stored synchronous spectra of the laboratory prepared mixtures 
were divided by the synchronous spectra of 0.1 µg/ml of each of 
standard TAD and DAP then first coefficients of CWT of the obtained 
ratio spectra were calculated. The amplitude values of the obtained 
spectra were recorded at 302 nm and 342 nm for TAD and DAP, 
respectively. The concentrations of the drugs were calculated from 
the corresponding computed regression equations. 
Savitzky-Golay (SAVGOL) method 
The first derivative of the stored synchronous spectra of the 
laboratory prepared mixtures was calculated by SAVGOL method. 
The amplitude values of the obtained spectra were recorded at 330 
nm and 312 nm for TAD and DAP, respectively. The concentrations 
of both drugs were calculated from the corresponding computed 
regression equations. 
Application to pharmaceutical formulation 
Ten tablets of Super-Tadarise® 
The proposed methods were applied for the analysis of the studied 
drugs in their pharmaceutical formulation using the procedures 
mentioned under the analysis of laboratory prepared mixtures for 
each method and the concentrations of the cited drugs were 
calculated from the corresponding regression equations. 
[labeled to contain 20 mg TAD and 
60 mg DAP] were accurately weighed and finely powdered. An 
accurate weight of powder equivalent to 10 mg TAD and 30 mg DAP 
was transferred into a 100-mL volumetric flask, sonicated with 50 
mL methanol for 15 min and diluted to volume with the same 
solvent. The solution (100 µg/ml TAD and 300 µg/ml DAP) was 
sonicated again for 10 min and filtered. An aliquot (0.01 mL) was 
transferred to a 10-mL volumetric flask and completed to volume 
with methanol to give final concentration equivalent to 0.1 µg/ml 
TAD and 0.3 µg/ml DAP.  
RESULTS AND DISCUSSION 
By reviewing the literature, it was found that no spectrofluorimetric 
methods have been developed for the simultaneous determination 
of TAD and DAP in their binary mixture without prior separation 
which adds novelty to the proposed methods. Moreover, the 
developed methods offer higher sensitivity than the reported 
spectrophotometric methods [32].  
In this work, two spectrofluorimetric methods coupled with CWT 
and SAVGOL derivatization technique were developed for the 
simultaneous determination of TAD and DAP in their bulk powders 
and pharmaceutical dosage forms.  
The developed methods were simple, sensitive and selective with 
good precision and accuracy. They were successfully applied for the 
determination of TAD and DAP in their bulk powders and 
pharmaceutical formulations. 
TAD was found to exhibit native fluorescence at λem of 331 nm, 
after excitation at 227 nm, and DAP also showed native fluorescence 
at λem of 339 nm after excitation at 227 nm. The emission spectra of 
both drugs show severe overlap, [fig. 3]. 
Synchronous fluorescence spectra using Δ λ 0f 20 nm were recorded 
for both drugs, [fig. 4]. The synchronous spectra of TAD and DAP 
resulted in a better resolution and more featured spectra than the 
conventional ones, but the spectra of the two drugs are still 
overlapped which hinders their direct determination. Different 
experimental and instrumental parameters were found to affect the 
shape and intensity of the synchronous spectra. These parameters 
were studied and-and optimized using 0.1 µg/ml TAD and DAP. They 
include the diluting solvent, Δ λ, response time, excitation and 
emission bandwidths and the instrument sensitivity. 
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Fig. 3: Emission spectra of 0.1 µg/ml of each of Tadalafil and 
Dapoxetine HCl in methanol 
 
 
Fig. 4: Synchronous fluorescence spectra of 0.1 µg/ml of each of 
Tadalafil and Dapoxetine HCl 
 
Dilutions with different organic and inorganic solvents were tried 
including methanol, ethanol, acetonitrile, water, 0.1 N HCl and 0.1 M 
sulfuric acid.  
Organic solvents showed higher fluorescence intensities than 
inorganic solvents. Methanol was selected for dilution as it showed 
higher fluorescence intensity and better linearity compared to other 
organic solvents. 
Different excitation bandwidths were tried (5, 10 and 20 nm) while 
keeping the emission bandwidth constant and vice versa. Both the 
excitation and emission bandwidths were fixed at 5 nm, where they 
provide reasonable intensities. 
The choice of the optimum Δ λ value is a critical factor for 
performing SFS. It can directly affect the spectral shape, bandwidth, 
and signal value. Different Δ λ values were examined (20–100 nm). Δ 
λ of 20 nm was chosen as it resulted in the narrower spectral band, 
better resolution and higher intensity of spectral features.  
 
 
Fig. 5: Synchronous fluorescence spectra of Tadalafil (0.03 
µg/ml–3 µg/ml) in methanol 
The instrument was adjusted at auto response time. High sensitivity 
was chosen to increase the fluorescence intensity. 
Aliquots of TAD and DAP standard solutions were diluted with 
methanol to give final concentrations of 0.01–3 µg/ml and 0.01–1.2 
µg/ml of TAD and DAP, respectively. They were then scanned for their 
synchronous fluorescence spectra using Δ λ of 20 nm, [fig. 5 and 6]. 
 
 
Fig. 6: Synchronous fluorescence spectra of Dapoxetine HCl 
(0.01 µg/ml–1.2 µg/ml) in methanol 
 
Continuous wavelet transforms (CWT) 
The synchronous spectra of TAD and DAP were divided by 0.1 µg/ml 
of each of DAP and TAD, respectively, and the ratio spectra were 
obtained, as shown in [fig. 7 and 8]. 
 
 
Fig. 7: Ratio spectra of Tadalafil (0.01–3 µg/ml) in methanol using 
standard spectrum of 0.1 µg/ml of Dapoxetine HCl as a divisor 
 
 
Fig. 8: Ratio spectra of Dapoxetine HCl (0.01–1.2 µg/ml) in 
methanol using standard spectrum of 0.1 µg/ml of Tadalafil as a 
divisor 
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First coefficients of CWT of ratio spectra were calculated using a 
scale of 25, [fig. 9 and 10]. TAD showed two peak maxima at 302 nm 
and 317 nm, also DAP showed two peak maxima at 328 nm and 345 nm. 
TAD and DAP were determined at 302 nm and 328 nm, respectively, 
owing to the better correlation coefficients obtained on calibration. 
 
 
Fig. 9: First coefficients of CWT of ratio spectra of Tadalafil 
(0.03–3 µg/ml) in methanol using standard spectrum of 0.1 
µg/ml of Dapoxetine HCl as a divisor 
 
 
Fig. 10: First coefficients of CWT of ratio spectra of Dapoxetine 
HCl (0.01–1.2 µg/ml) in methanol using standard spectrum of 
0.1 µg/ml of Tadalafil as a divisor 
The concentrations of TAD and DAP in the mixtures could be 
obtained from the corresponding regression equations (obtained by 
plotting the amplitude values at 302 nm and 328 nm for TAD and 
DAP, respectively against the corresponding concentrations).  
Savitzky-Golay (SAVGOL) method 
First derivative of the synchronous fluorescence spectra of TAD and 
DAP were calculated by SAVGOL technique using a width of 50, [fig. 
11]. TAD was determined at 330 nm and DAP were determined at 
312 nm which corresponds to the zero crossing points of DAP and 
TAD, respectively.  
 
 
Fig. 11: First derivative spectra of Tadalafil (0.01–3 µg/ml) and 
Dapoxetine HCl (0.01–1.2 µg/ml) in methanol calculated by 
SAVGOL function 
 
The concentrations of TAD and DAP in the mixtures could be 
obtained from the corresponding regression equations (obtained by 
plotting the amplitude values at 330 nm and 312 nm for TAD and 
DAP, respectively against the corresponding concentrations).  
Method validation 
Validation was performed according to ICH guidelines [36]. 
Linearity and range 
The linearity of the proposed methods was assessed by analyzing six 
concentrations of TAD and DAP ranging from 0.01–3 µg/ml and 
0.01–1.2 µg/ml, respectively. The assay was performed according to 
the previously mentioned experimental conditions, and the linear 
equations are summarized in [table 1]. 
 
Table 1: Regression and validation parameters for the determination of Tadalafil and DapoxetineHCl in their pure forms by the proposed 
methods 
Parameter Tadalafil Dapoxetine HCl 
CWT at 302 nm SAVGOL at 330 nm CWT at 328 nm SAVGOL at 312 nm 
Range (µg/ml) 0.01–3  0.01–3  0.01–1.2  0.01–1.2  
Slope 87.192 6.7809 632.78 15.7624 
Intercept 2.0458 0.2098 5.2213 -0.2330 
*SE of the slope 0.8089 0.0600 8.077 0.2017 
SE of the intercept 1.2470 0.0925 5.890 0.1609 
Correlation coefficient (r) 0.9998 0.9998 0.9997 0.9997 
*LOD (µg/ml) 0.024 0.0102 0.008 0.009 
*LOQ (µg/ml) 0.073 0.0310 0.023 0.027 
**Accuracy (mean±SD) 98.98±1.826 100.34±1.699 99.90±1.047 99.80±1.154 
**Specificity (mean±SD) 100.68±1.898 99.78±1.670 99.29±1.551 100.68±1.413 
Precision (RSD%)     
Repeatability  1.176 1.062 1.489 1.277 
Intermediate precision  1.680 0.874 0.529 0.489 
*SE (Standard error)., **Average of five determinations., *LOD(limit of detection)., *LOQ(limit of quantitation). 
 
Accuracy 
The accuracy of the results was checked by applying the proposed 
methods for determination of different individual samples of pure 
TAD and DAP. The concentrations were obtained from the 
corresponding regression equations. The percentage recoveries, 
mean recoveries, and relative standard deviations were calculated 
and showed good accuracy for the proposed methods. [table 1]. 
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Selectivity of the proposed methods was assessed by the analysis of 
different laboratory prepared mixtures of TAD and DAP within the 
linearity range. Satisfactory results were obtained as shown in [table 2]. 
Precision  
Repeatability and intermediate precision  
Freshly prepared solutions of concentrations 0.7, 2 and 3 µg/ml of 
TAD and 0.5, 0.7 and 0.9 µg/ml of DAP were assayed in triplicates 
within the same day and inter-daily on three successive days by the 
proposed methods. The relative standard deviations were then 
calculated, [table 1]. 
Application to pharmaceutical preparation 
The proposed methods were applied for the determination of TAD 
and DAP in their combined pharmaceutical formulation, Super 
Tadarise®
The results obtained for the analysis of both drugs in their pure forms by 
the proposed methods were statistically compared to those obtained by 
applying a reported HPLC method [30]. The values of the calculated t and 
F values are less than the tabulated ones which reveal that there is no 
significant difference between the proposed methods and the reported 
one with respect to accuracy and precision, [table 5]. 
 tablets. The accuracy of the method was further assessed 
by applying the standard addition technique, and the results are 
shown in [tables 3 and 4].  
 
Table 2: Results of determination of Tadalafil and Dapoxetine HCl in laboratory prepared mixtures by the proposed methods 
Tadalafil Dapoxetine HCl 

























0.200 0.205 102.50 0.200 0.201 100.50 0.600 0.581 96.83 0.600 0.592 98.67 
0.700 0.689 98.43 0.700 0.681 97.29 1.200 1.191 99.25 0.700 0.709 101.29 
0.500 0.513 102.60 0.500 0.508 101.60 0.700 0.702 100.29 0.900 0.917 101.89 
1.000 1.007 100.70 1.000 1.005 100.50 0.900 0.908 100.89 0.500 0.509 101.80 

















*Average of three determinations 
 
Table 3: Results obtained by applying the proposed CWT method for the determination of Tadalafil and DapoxetineHCl in Super-
Tadarise®
Tadalafil 
 tablets and application of standard addition technique 
Dapoxetine HCl 
Super-Tadarise®
(Batch No. ST1514) 
 tablets Standard addition Super-Tadarise®
(Batch No. ST1514) 


















0.100 0.100 100.00 0.080 0.079 98.75 0.300 0.303 101.00 0.100 0.098 98.00 
0.099 99.00 0.100 0.101 101.00 0.305 101.67 0.300 0.299 99.67 
0.098 98.00 0.12 0.117 97.50 0.304 101.33 0.500 0.499 99.80 
Mean 99.00 Mean 99.08 Mean 101.33 Mean 99.16 
 RSD% 1.010  RSD% 1.790  RSD% 0.331  RSD% 1.012 
*Average of three determinations 
 
Table 4: Results obtained by applying the proposed SAVGOL method for the determination of Tadalafil and Dapoxetine HCl in Super-
Tadarise®
Tadalafil 
 tablets and application of standard addition technique 
Dapoxetine HCl 
Super-Tadarise®
(Batch No. ST1514) 
 tablets Standard addition Super-Tadarise®
(Batch No. ST1514) 


















0.100 0.101 101.00 0.080 0.082 102.50 0.300 0.305 101.67 0.100 0.102 102.00 
0.099 99.00 0.100 0.103 103.00 0.305 101.67 0.300 0.300 100.00 
0.096 96.00 0.12 0.122 101.67 0.307 102.33 0.500 0.495 99.00 
Mean 98.67 Mean 102.39 Mean 101.89 Mean 100.33 
 RSD% 2.551  RSD% 0.656  RSD% 0.374 RSD% 1.522 
*Average of three determinations. 
 
CONCLUSION 
Synchronous fluorescence spectroscopy is more advantageous than 
conventional spectrofluorimetry due to narrowing of the spectral 
band and simplification of emission spectra which results in sharper 
and narrower peaks. The developed spectrofluorimetric methods 
offer high sensitivity and selectivity for the simultaneous 
determination of TAD and DAP in their binary mixture. Both CWT 
and SAVGOL techniques have the advantage of combining smoothing 
and differentiation in a single operation. They enhance the signal to 
noise ratio without deterioration of the signal compared to a 
derivative calculation by numerical differentiation. The proposed 
methods are simple precise and don’t need any sophisticated 
apparatus. They could be applied in quality control laboratories for the 
routine analysis of the studied drugs either in their bulk powders or in 
pharmaceutical dosage forms without preliminary separation. 
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Table 5: Statistical comparison of the results obtained by the proposed methods and the reported HPLC method for the determination of 
Tadalafil and DapoxetineHCl in their pure forms 










Mean 98.98 100.34 99.70 99.89 99.80 99.56 
SD 1.854 1.699 0.921 1.048 1.153 0.917 
n 5 5 5 5 5 5 
Variance 3.438 2.887 0.848 1.098 1.330 0.842 
t-test  1.223(2.306)* *  0.740(2.447)*   0.547(2.306)*  0.373(2.306)*  
F  1.100(6.388)* *  3.406(6.388)*   1.287(6.388)* 1.580(6.388)*  
*
 
The fig. in parenthesis are the corresponding theoretical values at p=0.05., **HPLC method (C-18, using methanol: acetonitrile: triethylamine in the 
ratio of 95: 5: 0.5 v/v/v at a flow rate of 1 mL/min and detection at 290 nm). 
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